Relationships Between Components of Blood Pressure and Cardiovascular Events in Patients with Stable Coronary Artery Disease and Hypertension
暂无分享,去创建一个
Deepak L. Bhatt | A. Parkhomenko | J. Tardif | R. Ferrari | M. Tendera | I. Ford | P. Steg | K. Fox | E. Vidal-Petiot | N. Greenlaw
[1] P. Whelton,et al. Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis , 2017, JAMA cardiology.
[2] S. Bangalore,et al. Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta-Analysis of Randomized Trials. , 2017, The American journal of medicine.
[3] R. Ravindrarajah,et al. Systolic Blood Pressure Trajectory, Frailty, and All-Cause Mortality >80 Years of Age: Cohort Study Using Electronic Health Records , 2017, Circulation.
[4] Deepak L. Bhatt,et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study , 2016, The Lancet.
[5] Deepak L. Bhatt. Troponin and the J-Curve of Diastolic Blood Pressure: When Lower Is Not Better. , 2016, Journal of the American College of Cardiology.
[6] J. Coresh,et al. 60 A comparison of HFrEF vs HFpEF’s clinical workload and cost in the first year following hospitalisation and enrollment in a disease management program , 2016, Journal of the American College of Cardiology.
[7] D. Wood,et al. The Impact of Left Ventricular Mass on Diastolic Blood Pressure Targets for Patients With Coronary Artery Disease. , 2016, American journal of hypertension.
[8] G. Mancia,et al. Unattended Blood Pressure Measurements in the Systolic Blood Pressure Intervention Trial: Implications for Entry and Achieved Blood Pressure Values Compared With Other Trials , 2016, Hypertension.
[9] G. Mancia,et al. Unobserved automated office blood pressure measurement in the Systolic Blood Pressure Intervention Trial (SPRINT): systolic blood pressure treatment target remains below 140 mmHg. , 2016, European heart journal. Cardiovascular pharmacotherapy.
[10] S. Anderson,et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.
[11] Deepak L. Bhatt,et al. Pulse Pressure and Risk for Cardiovascular Events in Patients With Atherothrombosis: From the REACH Registry. , 2016, Journal of the American College of Cardiology.
[12] P. Meredith,et al. Prognostic importance of pretreatment and on-treatment blood pressure: Further analysis of the ACTION database and the effect of nifedipine gastrointestinal therapeutic system , 2016, Blood pressure.
[13] J. McMurray,et al. Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. , 2015, European heart journal.
[14] D. Levy,et al. Does Low Diastolic Blood Pressure Contribute to the Risk of Recurrent Hypertensive Cardiovascular Disease Events?: The Framingham Heart Study , 2015, Hypertension.
[15] J. Tardif,et al. Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry. , 2014, JAMA internal medicine.
[16] R. Conwit,et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial , 2013, The Lancet.
[17] S. Bangalore,et al. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. , 2010, European heart journal.
[18] G. Mancia,et al. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. , 2009, European heart journal.
[19] D. Levy,et al. Single Versus Combined Blood Pressure Components and Risk for Cardiovascular Disease: The Framingham Heart Study , 2009, Circulation.
[20] J. Filipovský,et al. Diastolic Blood Pressure and Mortality in the Elderly With Cardiovascular Disease , 2007, Hypertension.
[21] Michael Böhm,et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension , 2007, Blood pressure.
[22] R. Vasan,et al. Aggressive lowering of blood pressure , 2006, The Lancet.
[23] G. Mancia,et al. Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous? , 2006, Annals of Internal Medicine.
[24] R. D'Agostino,et al. A likely explanation for the J-curve of blood pressure cardiovascular risk. , 2004, The American journal of cardiology.
[25] Anthony F. Lever,et al. Implications of Pulse Pressure as a Predictor of Cardiac Risk in Patients With Hypertension , 2000, Hypertension.
[26] R H Fagard,et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. , 1999, Archives of internal medicine.
[27] C. Escobar Cervantes,et al. [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.
[28] Kevin A Peterson,et al. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .
[29] W. Elliott. The J-Curve Between Blood Pressure and Coronary Artery Disease or Essential Hypertension: Exactly How Essential? , 2010 .
[30] M. Safar. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. , 1994, Hypertension.